Tim Pearson, Elaine Sullivan. (LinkedIn, Carrick)
July 1, 2019 06:45 AM EDT
People

Tesaro vet jumps to an Irish on­col­o­gy up­start and shifts fo­cus to the US, eye­ing fundrais­ing

John Carroll

Editor & Founder

Tim Pear­son’s biotech break is over.

Af­ter pick­ing up a $12 mil­lion pay­out late last year fol­low­ing the sale of Tesaro to GSK, the for­mer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times